Web Toolbar by Wibiya
Login | Sign Up AnonymousUser
twiter
New to Comunitee?


or Sign Up with Email

Business

>> ASTRAZENECA Latest News

JAN 29, 2015 - Wall Street Journal

A Must Read - Share

AstraZeneca to Harness Benefits of Genome-Editing Technology

AstraZeneca has unveiled agreements that should enable the U.K. pharmaceutical company to tap into a promising, nascent gene technology aimed at making drugs more precise.

Tags: AstraZeneca to Harness Benefits of Genome-Editing Technology,  Astrazeneca Latest News

JAN 27, 2015 - TheStreet

A Must Read - Share

Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy

PRINCETON, NJ (TheStreet) -- Advaxis stopped using The Dream Team Group in November 2013, so tying responsibility for the company's quadrupled stock price over the past two months to the work of the notorious stock-promotions firm -- as Seeking Alpha's Richard Pearson did last week -- misses the mark. There are better reasons to explain why Advaxis shares jumped from $3 in ...

Tags: Advaxis: Legit Reasons to Take Another Look at Under-Appreciated Cancer Immunotherapy,  Astrazeneca Latest News

JAN 26, 2015 - Zacks Investment Research

A Must Read - Share

AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog

AstraZeneca (AZN) announced that its Marketing Authorisation Application for the approval of lesinurad was accepted by the EMA.

Tags: AstraZeneca's Regulatory Filing for Lesinurad Accepted - Analyst Blog,  Astrazeneca Latest News

JAN 22, 2015 - Benzinga

A Must Read - Share

Leerink Raises AstraZeneca Price Target

Leerink on Thursday raised AstraZeneca plc (ADR) (NYSE: AZN) one-year price target to $77.00 from $76.00 based on a revision of earnings estimates for AstraZeneca's drug Brilinta. Latest Ratings for AZN DateFirmActionFromTo Jan 2015BarclaysDowngradesEqualweightUnderweight Dec 2014Morgan StanleyDowngradesEqualweightUnderweight Jul 2014JP MorganReinstatesUnderweight View More Analyst Ratings for AZN View the Latest Analyst Ratings

Tags: Leerink Raises AstraZeneca Price Target,  Astrazeneca Latest News

JAN 21, 2015 - TheStreet

A Must Read - Share

Stocks Slide From Session Highs as Healthcare Sector Stumbles

NEW YORK (TheStreet) -- Equity markets slid from session highs on Wednesday, dragged lower by laggards in the healthcare sector. Merck was leading sector losses on the Dow Jones Industrial Average after the company said it will withdraw its hepatitis C medicine from U.S. shelves due to weak demand partially a result of Gilead Sciences' increasing dominance in the space. Shares were down ...

Tags: Stocks Slide From Session Highs as Healthcare Sector Stumbles,  Astrazeneca Latest News